<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437044</url>
  </required_header>
  <id_info>
    <org_study_id>ESR 13396</org_study_id>
    <nct_id>NCT03437044</nct_id>
  </id_info>
  <brief_title>Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI</brief_title>
  <acronym>OPTIMUS-6</acronym>
  <official_title>A Randomized Comparison of Platelet Inhibition Using a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-6 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid&#xD;
      dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in&#xD;
      patients with DM who are known to have impaired response to clopidogrel therapy. Since DM&#xD;
      patients frequently require elective PCI due to chronic progression of CAD (and not solely&#xD;
      because of an acute thrombotic complication), and clopidogrel remains the guideline&#xD;
      recommended P2Y12 inhibiting therapy for these patients, understanding the PD effects of the&#xD;
      ticagrelor 60 mg bid regimen in this setting is an unmet clinical need. This is also in light&#xD;
      of the ongoing THEMIS trial which is specifically evaluating the impact of the ticagrelor 60&#xD;
      mg bid dosing regimen in type 2 DM patients without a prior major CV event.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diabetes mellitus (DM) are characterized by platelet hyperreactivity and&#xD;
      reduced pharmacodynamic (PD) effects to several oral antiplatelet agents, including&#xD;
      clopidogrel. In addition to the hyperreactive platelet phenotype, impaired drug metabolism as&#xD;
      well as increased platelet turnover rates may contributed to impaired clopidogrel-induced&#xD;
      antiplatelet effects in DM patients. These observations may contribute to the higher ischemic&#xD;
      event rates, including stent thrombosis, observed in DM patients compared with non-DM&#xD;
      patients treated with clopidogrel.&#xD;
&#xD;
      Ticagrelor is characterized by more prompt, potent and predictable antiplatelet effects&#xD;
      compared with clopidogrel and lower ischemic events in patients with an acute coronary&#xD;
      syndrome (ACS) on a background of aspirin therapy. In patients who experienced a prior (1-3&#xD;
      years) myocardial infarction (MI), compared with placebo, ticagrelor 60 mg bid on a&#xD;
      background of aspirin therapy also reduced long-term ischemic events, with a mortality&#xD;
      benefit observed in DM patients.&#xD;
&#xD;
      To date the PD effects of ticagrelor versus clopidogrel in DM largely derive from post-hoc&#xD;
      assessments or in stabilized patients (e.g. &gt;30 days after PCI), and have not been&#xD;
      prospectively evaluated in the context of elective PCI procedures. Moreover, PD studies with&#xD;
      the ticagrelor 60 mg bid regimen are limited. Therefore, the aim of this investigation will&#xD;
      be to compare the PD effects of a ticagrelor 60 mg bid versus clopidogrel 75 mg od MD regimen&#xD;
      in DM patients without a prior major CV event undergoing elective PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Actual">June 27, 2020</completion_date>
  <primary_completion_date type="Actual">June 27, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Staff performing PK/PD assessments will remain blinded to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>P2Y12 Reaction Units (PRU)</measure>
    <time_frame>30 days</time_frame>
    <description>The primary endpoint of our study will be platelet reactivity, measured as PRU level using VerifyNow PRU, of ticagrelor versus clopidogrel MD at 30 days after PCI, immediately pre-dosing dosing (trough levels).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Index (PRI)</measure>
    <time_frame>30 days</time_frame>
    <description>Platelet reactivity measured as PRI% using whole blood vasodilator-stimulated phosphoprotein (VASP), of ticagrelor versus clopidogrel MD at 30 days after PCI, immediately pre-dosing dosing (trough levels).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Men or women ≥18 years of age&#xD;
&#xD;
          3. Diagnosed with type 2 DM defined by ongoing glucose lowering drug (oral medications&#xD;
             and / or insulin) treatment for at least 1 month&#xD;
&#xD;
          4. Presence of CAD undergoing elective PCI* * Patients will need to be cardiac&#xD;
             enzyme-negative prior to undergoing coronary angiography. Patient will need to be on a&#xD;
             background of aspirin therapy (treated with a 325 mg LD prior to coronary angiography&#xD;
             unless already on chronic low-dose aspirin therapy). Patients on maintenance&#xD;
             clopidogrel 75 mg therapy for at least 1 week due to a prior vascular intervention&#xD;
             will also be eligible. However, patients on clopidogrel, ticagrelor or prasugrel due&#xD;
             to a prior acute major cardiovascular event (MI or stroke) will not be eligible.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Previous MI (with the exception of definite non-type 1 MI [eg, due to coronary&#xD;
             revascularization procedure, profound hypotension, hypertensive emergency,&#xD;
             tachycardia, or profound anemia])&#xD;
&#xD;
          2. Previous stroke (transient ischemic attack [TIA] is not included in the stroke&#xD;
             definition)&#xD;
&#xD;
          3. Use of an intravenous antiplatelet therapy (i.e., cangrelor or GPI) during PCI&#xD;
&#xD;
          4. On treatment with clopidogrel, prasugrel, or ticagrelor due to a prior acute major CV&#xD;
             event (MI or stroke) (on treatment with clopidogrel due to prior vascular intervention&#xD;
             not secondary to a major CV event is allowed)&#xD;
&#xD;
          5. Planned use of aspirin treatment at doses &gt;100 mg od&#xD;
&#xD;
          6. Anticipated concomitant oral or intravenous therapy with strong cytochrome P450 3A4&#xD;
             (CYP3A4) inhibitors or CYP3A4 substrates with narrow therapeutic indices that cannot&#xD;
             be stopped for the course of the study:&#xD;
&#xD;
               -  Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin,&#xD;
                  clarithromycin (but not erythromycin or azithromycin), nefazadone, ritonavir,&#xD;
                  saquinavir, nelfinavir, indinavir, atanazavir&#xD;
&#xD;
               -  CYP3A4 substrates with narrow therapeutic index: quinidine, simvastatin at doses&#xD;
                  &gt;40 mg daily or lovastatin at doses &gt;40 mg daily&#xD;
&#xD;
          7. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin&#xD;
             (at venous thrombosis treatment not prophylaxis doses)&#xD;
&#xD;
          8. Patients with known bleeding diathesis or coagulation disorder&#xD;
&#xD;
          9. History of previous intracerebral bleed at any time, gastrointestinal (GI) bleed&#xD;
             within the past 6 months prior to randomization, or major surgery within 30 days prior&#xD;
             to randomization&#xD;
&#xD;
         10. Active pathological bleeding&#xD;
&#xD;
         11. Hypersensitivity to ticagrelor and clopidogrel or any of the excipients&#xD;
&#xD;
         12. Increased risk of bradycardic events (eg, known sick sinus syndrome, second or third&#xD;
             degree AV block or previous documented syncope suspected to be due to bradycardia)&#xD;
             unless treated with a pacemaker&#xD;
&#xD;
         13. Known severe liver disease (eg, ascites and/or clinical signs of coagulopathy)&#xD;
&#xD;
         14. Renal failure requiring dialysis&#xD;
&#xD;
         15. Known platelet count &lt;80x106/mL&#xD;
&#xD;
         16. Known hemoglobin &lt;9 g/dL&#xD;
&#xD;
         17. Women of child-bearing potential (ie, those who are not chemically or surgically&#xD;
             sterilized or who are not post-menopause) who are not willing to use a medically&#xD;
             accepted method of contraception that is considered reliable in the judgment of the&#xD;
             investigator OR who have a positive pregnancy test at enrolment or randomization OR&#xD;
             women who are breast-feeding. If a subject becomes pregnant during the course of the&#xD;
             study the investigational product should be discontinued immediately [the outcome of&#xD;
             all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy,&#xD;
             normal birth or congenital abnormality) will be followed up and documented even if the&#xD;
             subject was discontinued from the study].&#xD;
&#xD;
         18. Inability of the patient to understand and/or comply with study procedures and/or&#xD;
             follow up, in the opinion of the investigator, OR any conditions that, in the opinion&#xD;
             of the investigator, may render the patient unable to complete the study&#xD;
&#xD;
         19. Life expectancy of less than 1 month based on investigator's judgement&#xD;
&#xD;
         20. Participation in another clinical study with an investigational (defined as non-FDA&#xD;
             approved) product within 28 days prior to enrolment&#xD;
&#xD;
         21. Previous randomization in the present study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick J Angiolillo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <results_first_submitted>January 19, 2021</results_first_submitted>
  <results_first_submitted_qc>January 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2021</results_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03437044/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03437044/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor</title>
          <description>180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD&#xD;
Ticagrelor: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel</title>
          <description>600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD&#xD;
Clopidogrel: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor</title>
          <description>180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD&#xD;
Ticagrelor: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel</title>
          <description>600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD&#xD;
Clopidogrel: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="7"/>
                    <measurement group_id="B2" value="66" spread="9"/>
                    <measurement group_id="B3" value="66" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>P2Y12 Reaction Units (PRU)</title>
        <description>The primary endpoint of our study will be platelet reactivity, measured as PRU level using VerifyNow PRU, of ticagrelor versus clopidogrel MD at 30 days after PCI, immediately pre-dosing dosing (trough levels).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD&#xD;
Ticagrelor: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD&#xD;
Clopidogrel: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>P2Y12 Reaction Units (PRU)</title>
          <description>The primary endpoint of our study will be platelet reactivity, measured as PRU level using VerifyNow PRU, of ticagrelor versus clopidogrel MD at 30 days after PCI, immediately pre-dosing dosing (trough levels).</description>
          <units>PRU</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="32" upper_limit="89"/>
                    <measurement group_id="O2" value="146" lower_limit="106" upper_limit="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Index (PRI)</title>
        <description>Platelet reactivity measured as PRI% using whole blood vasodilator-stimulated phosphoprotein (VASP), of ticagrelor versus clopidogrel MD at 30 days after PCI, immediately pre-dosing dosing (trough levels).</description>
        <time_frame>30 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor</title>
          <description>180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD&#xD;
Ticagrelor: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel</title>
          <description>600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD&#xD;
Clopidogrel: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dominick J. Angiolillo, MD, PhD</name_or_title>
      <organization>University of Florida</organization>
      <phone>9042443378</phone>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

